Corrine M. Carter
FDA investigator
Appears on 2 documents from 2018 to 2025, mostly at sites in Indiana. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(c)(2)).
- 2
- Documents on file
- 2.5
- Observations per 483
- 2018
- First seen
- 2025
- Most recent
What they cite most
From 5 observations- 21 CFR 314.80(c)(2)Postmarketing reporting of adverse drug experiences1
- 21 CFR 58.190Storage and retrieval of records and data1
- 21 CFR 58.33Study director1
- 21 CFR 58.35Quality assurance unit1
- 21 CFR 58.63Maintenance and calibration of equipment1
- 21 CFR 58.81Standard operating procedures1
Activity by year
2018: 1, 2025: 1
Where
Indiana 1 · New York 1
Often inspects with
Is Corrine M. Carter coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2025-05-29 | 483 BASF CorporationMay 29, 2025 · East Setauket, New York | East Setauket, New York | 4 | |
| 2018-04-23 | 483 Eli Lilly and CompanyApr 23, 2018 · Indianapolis, Indiana | Indianapolis, Indiana | 1 |
About this profile
What does Corrine M. Carter inspect?
Corrine M. Carter appears on 2 documents on file covering 2 sites, mostly in Indiana.
What do they cite most often?
21 CFR 314.80(c)(2) (postmarketing reporting of adverse drug experiences), followed by 21 CFR 58.190 and 21 CFR 58.33.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Corrine M. Carter is dated May 29, 2025.